|
|
Speakers 
Mr Nicholas Adams,
Director Business Development,
Antisoma
|
Dr Robert S Adamson,
Vice President,
Wyeth Biopharma Development Network
|
Dr Vivian Albert,
Vice President,
Human Genome Sciences Inc
|
 Dr Dana Ault-Riche,
CEO,
Pointilliste
Dr. Dana Ault-Riché is the Founder and CEO of Pointilliste. Dr. Ault-Riché also founded two other biotech companies - Zyomyx (Hayward, CA) and Diazyme-General Atomics (La Jolla, CA). He received his PhD in Biochemistry from the University of Kansas and did post-doctoral work with Nobel Laureate Arthur Kornberg at Stanford University.
|
Dr Patrick Baeuerle,
Professor of Immunology & Chief Scientific Officer,
Micromet AG
|
 Dr Sylvio Bengio,
Scientific Communications Specialist,
Pall Life Sciences
Dr. Sylvio Bengio received his Doctorate in ‘Cellular & Molecular Biology’ from the University of Rouen, France. During this time he also conducted research in the field of Cellular Immunology on ‘Fc Receptors & Regulation of the Complement Response’ at the ‘National Institute of Health & Medicine’ (INSERM).
Since joining industry, Dr Bengio has accumulated over 18 years experience in Downstream Processing and Protein Purification. Working for Pall BioSepra he specialises in Chromatography Process Development, Application of Novel Technologies and Scientific Communications.
|
 Professor John Birch,
Chief Scientific Officer,
Lonza Biologics
John Birch graduated in microbiology from London University where he also completed a Ph.D. After a period lecturing at the University he moved into industry, holding senior technical positions at Tate and Lyle, G.D. Searle, Celltech and Lonza. He is currently Chief Scientific Officer, Lonza Biopharmaceuticals. His scientific interests have focused on the production of therapeutic proteins, particularly from mammalian cells and he has published extensively in this field. He is a visiting Professor in the Department of Biochemical Engineering at University College London.
|
 Dr Bram Bout,
Vice President Protein Productio,
Crucell Holand N.V
Dr. Abraham (Bram) Bout is the Vice President of protein production at Crucell, where he is responsible for production of recombinant proteins on PER.C6®. Dr. Bout joined Introgene (which later merged with UbiSys to form Crucell) in 1993, and was director of the adenovirus research group until the end of 1999. One of the first achievements in this area was the development of the PER.C6® cell line in collaboration with Prof. Van der Eb and Dr. R.C. Hoeben from Leiden University. Dr. Bout’s post-doctorate work was in gene therapy for Cystic Fibrosis. Dr. Bout gained his PhD on peroxisomal storage disorders at the Academic Medical Centre in Amsterdam and studied chemistry at the University of Amsterdam, The Netherlands.
|
Dr Michael Braunagel,
Founder,
Affitech AS
|
Dr Paul Chamberlain,
Director, Biopharmaceuticals Drug Development Programs,
MDS Pharma Services
Paul Chamberlain specialises in regulatory and scientific aspects of the development of biopharmaceutical products. His approach is based on substantial experience of the characterisation of recombinant DNA-derived proteins, including monoclonal antibodies, gained during a period of more than 20 years. This extensive technical background is applied to the planning of development strategies for these molecules in a manner that anticipates product-specific regulatory challenges. His experience was gained with SmithKline Beecham, Amgen, Metris Therapeutics and Sanofi-Synthelabo. He joined MDS Pharma Services, a global CRO, in February 2001. In his role as Biopharmaceuticals Programme Director, Paul works closely with European- and North American-based clients to facilitate the planning and execution of regulatory-compliant, biopharmaceutical development projects. He is a member of The Organisation for Professionals in Regulatory Affairs (TOPRA) and of the ABPI Biotechnology Quality Group. Paul has a strong interest in the regulatory risk assessment of the immunogenicity of therapeutic proteins, particularly in relation to the demonstration of biopharmaceutical product comparability.
|
 Dr Bernard Chan,
Head of Biologicals Manufacturing Development,
UCB Celltech
Dr Bernard Chan is Head of Biological Manufacturing Development at UCB (formerly Celltech). He is responsible for supply of biological pipeline products via a strategy of in-house and outsourced manufacturing activities. Previous positions held include Senior Biologicals Manufacturing Development Manager at Celltech, Product Development Manager at Medeva and Project Team Leader at Delta Biotechnology. In these roles, he has worked with a variety of expression systems, including microbial, mammalian and yeast. Dr Chan holds a BSc and PhD in Biochemistry, specialising in molecular biology, and has worked in the Biotech / Biopharmaceutical industry for over 15 years. His achievements include establishing long-term manufacturing alliances, European approval of a recombinant biotech product, involvement in design and construction of manufacturing facilities and co-founding of a start-up biotech company.
|
 Dr Bassil Dahiyat, Ph.D,
President and Chief Executive Officer,
Xencor, Inc
Dr. Dahiyat is co-founder of Xencor™, and co-inventor of Xencor’s breakthrough biotechnology, Protein Design Automation™ (PDA). Following the development of PDA at the California Institute of Technology (Caltech), Dr. Dahiyat has been Xencor’s president and chief executive officer since the Company’s incorporation in August 1997.
Dr. Dahiyat holds a Ph.D. in Chemistry from Caltech and B.S. and M.S.E. degrees in Biomedical Engineering from the Johns Hopkins University. He has co-authored numerous scientific papers in the fields of protein design and drug delivery, and has received scientific awards from the American Chemical Society, the Controlled Release Society, the Protein Society and Caltech. Dr. Dahiyat currently holds a part-time appointment as Visiting Associate in Biology at Caltech.
|
Nitin Damle,
Department of Oncology,
Wyeth
Dr. Damle received his pre-doctoral training in cancer biology and immunology at Tata Cancer Research Center, Mumbai, India and Memorial Sloan-Kettering Cancer Center, New York, NY, USA. He further received his post-doctoral training in human immunogenetics and immunoregulation at Stanford University School of Medicine, Palo Alto, CA. Subsequently, he held scientific positions at then Cetus Corporation, now part of Chiron Corporation, Emeryville, CA and Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA before joining Wyeth Pharmaceuticals where he is currently Director of Discovery Oncology Research at Pearl River, NY and runs Wyeth's Discovery research programs in antibody-based therapeutic strategies including antibody-targeted chemotherapy.
|
Jane Dancer,
Senior Manager, Business Development,
Cambridge Antibody Technology
|
 Dr Hans de Haard,
Director of Technology Development,
Ablynx
Prior to joining Ablynx, Dr De Haard was Manager in the Functional Biomolecules group at Unilever Research Laboratories in Vlaardingen. In that position he was in charge of the research program within Unilever concerning applications of camelid single-domain antibodies for several Unilever consumer product groups. Previously he was Project Leader in Antibody Engineering at Organon. He received his PhD from the University of Maastricht and has carried-out post-doctoral research in the area of antibody engineering for diagnostic applications.
|
 Mr John Dingerdissen,
Vice President, Worldwide Manufacturing, Global Biologics Supply Chain LLC,
Johnson & Johnson
John Dingerdissen obtained his Masters of Science in Medicinal Chemistry from The School of Pharmacy, Purdue University in 1973. For several years he held the positions of increasing technical responsibility in Smith Kline and French Lab’s Biopharmaceutical R & D Division. His team produced clinical supplies of antibiotics, r-DNA molecules including tPA and various vaccines. He has published extensively in the field of the large-scale chromatography.
He completed the Wharton Evening Management Program at the University of Pennsylvania in 1985. After a period in R & D management he spent a few years as the head of DuPont’s Medical Products Division r-DNA pilot plant in Glasgow, DE.
In 1990, John assumed responsibility for developing a Technical Services group within Merck’s Vaccine Operations organization. After completing the start-up of the Varicella and Hepatitis A vaccines manufacturing facilities, John assumed responsibility for Bulk Vaccine Operations within Merck while the business grew 3-fold.
In 2001, John assumed his present position at Centocor responsible for Worldwide Manufacturing Operations including four plants and several contract manufacturing arrangements supplying ~$7.5 billion of biotech products.
Recently John has been a sought after speaker on such tops as “Follow-on Biological Products” at several venues in the past two years.
|
 Dr Sam Fazeli,
Biotechnology Analyst,
Nomura
Sam has been Senior Biotech Analyst at Nomura for 3 years. He began his career in 1996 as a Pharma analyst before moving into the biotech sector at HSBC where he was ranked No. 1 by Reuters. Sam joined Nomura from Altium where he was ranked 3rd by Reuters and 4th best UK small cap analyst by Extel. Nomura was ranked Number 1 in the Institutional Investor survey in 2003. Sam holds a BSc and a PhD in Pharmacology and has research into brain cell function. conducted 7 years of academic research into brain cell function.
|
Dr Ricarda Finnern,
Director,
Dyax
|
 Dr Philip Frost,
Chief Scientific Officer,
ImClone
Philip Frost, M.D., Ph.D., (64), joined ImClone Systems as Executive Vice President, Chief Scientific Officer on March 1, 2005. Prior to joining ImClone Systems, he was Vice President, Oncology at Wyeth Pharmaceuticals from 1995 to 2005. His group was responsible for expanding Wyeth’s oncology portfolio with 23 compounds. From 1992 to 1994 he served as Vice President, Oncology at Sandoz Pharmaceuticals (now Novartis). Before entering the industry, Dr. Frost was an endowed professor of the Cell Biology and Medicine at the MD Anderson Cancer Center.
|
 Dr Philipp Hess,
President and Founder,
Philipp Hess Associates
Philipp N. Hess is Founder and Managing Partner at PHA – Philipp Hess Associates.
Founded in 1994, PHA provides project and consulting services entirely dedicated to the global biopharmaceutical manufacturing sector with projects in Europe, USA, Latin America, and Far East.
Since 1999 PHA is a member of PMSA – Pharmaceutical and Medical Services Associates, Zürich, a strategic marketing and consulting organization with members in 5 European countries and the USA.
From 1988 to 1993 Philipp Hess worked in various positions at Centocor’s Therapeutics Division in The Netherlands and the USA; positions included Head of Logistics and Head of Project Management. He was deeply involved in the manufacturing development of successful monoclonal antibodies such as ReoPro and Remicade and less successful ones like Myoscint and the “textbook failure” Centoxin.
Philipp Hess holds a Doctor’s degree in biotechnology from the Department of Biotechnology at the Swiss Federal Institute of Technology, Zürich, Switzerland and a Master’s degree in chemistry from the Technical University of Munich.
|
 Mr Tim Hughes,
Managing Director,
Genentech Espana
TIM HUGHES is currently Managing Director, Genentech España, located in Porriño, Spain, dedicated to the manufacture of an anti-angiogenesis antibody, marketed as the anti-tumour drug Avastin™.
Tim has over 30 years of experience in biopharmaceuticals, with 18 years in management in manufacturing of human and veterinary products with market-leader organisations (Genentech Inc., Berlex Inc., The Wellcome Foundation), 3 years with Integrated Biosystems Inc. in California dedicated to developing and marketing technology-enabling solutions to bioprocess problems, and 10+ years of biotech consulting world-wide as Principal of his own company.
Tim is active in the biotechnology several industry forums, and a faculty member for education programs presented by the MBI® Training (Dept. of Biochemical Engineering, University College London, UK) and the Society of Bioprocessing Professionals in the US. He is co-patentee of the Asepco line of aseptic process valves. He holds an Honours degree in Applied Microbiology and Biochemistry.
|
 Lutz Jermutus,
Director Protein Engineering,
Cambridge Antibody Technology
Lutz Jermutus studied chemical engineering at the Universität Karlsruhe (TH) and majored in biotechnology at the Ecole Supérieure de Biotechnologie de Strasbourg. His studies included work on protein and enzyme engineering at the Institut Pasteur in Paris and at Hoffmann-La Roche in Basel. He then joined the research group of Andreas Plückthun at the Universität Zürich where he received his PhD in biochemistry on general strategies for protein selection and evolution with ribosome display. Since 2000 he has been working for Cambridge Antibody Technology (CAT) where he is currently Director of Protein Engineering.
At CAT Lutz established ribosome display where it became a method of choice for improving antibody affinity and potency. He then went on to translate the technology into an industrialised platform for the optimisation of protein therapeutics. The use of ribosome display has so far led to five pre-clinical drug candidates with potency improvements of over 10,000-fold. Lutz also devised and implemented the scientific training package for CAT's technology licensees that has been running successfully since 2002. Currently, his team's responsibilities include target generation, protein optimisation, HT protein sample preparation and protein & nucleic acid chemistry.
|
Mr Charles Kessler,
Directorate General Research,
European Commission
|
Mr Frank Landolt,
IP and Legal Counsel,
Ablynx N.V.
Frank Landolt is a Dutch (1994) and European (1995) patent attorney and a licensing lawyer. After studying chemistry (M.Sc., 1990) and law (M.Sc., 1992) at Leiden University, he worked for almost ten years at the private practice firms of Polak and Charlouis (now EP&C) and Nederlandsch Octrooibureau in the Netherlands, where his clients included large pharmaceutical companies as well as some of the premier biotech firms and research institutes in the Netherlands. Prior to joining Ablynx as IP and legal counsel in 2004, Frank worked for four years as director of IP and legal counsel at Devgen N.V.. Frank is a member of EPI, the Dutch Association of Patent Attorneys, LES and the Institut des Juristes d'Entreprise.
|
 Dr Torben Lund-Hansen,
Vice President, Manufacturing,
Genmab A/S
Torben Lund-Hansen has worked for Novo Nordisk for 16 years in a number of managerial positions in process development, biopharmaceutical manufacturing and international project management. From 2000 he worked for the American biotech company Maxygen responsible for process development and clinical manufacturing. The last three years he has worked for Genmab A/S as vice president responsible for process development and manufacturing. A network of external partners has been used for all physical activities.
Torben Lund-Hansen holds a M.Sc. in Biochemistry and Ph.D. in genetics from the University of Copenhagen.
|
Dr Robert J Lutz,
Senior Director,
ImmunoGen Inc
|
Dr Achilleas Mitsos,
Director-General DG Research,
European Commission
|
 Dr Simon Moroney,
CEO,
MorphoSys
Simon Moroney is CEO of MorphoSys AG and one of the company’s co-founders. Prior to co-founding MorphoSys, Dr. Moroney held positions in the Department of Pharmacology, University of Cambridge, Cambridge, U.K. (1991-92), as Assistant Professor in the Chemistry Department of the University of British Columbia, Vancouver, Canada (1989-1990) and as Associate in the Chemistry Department of the Eidgenössische Technische Hochschule (ETH), in Zurich, Switzerland (1986-1989), where he also held a position as Lecturer (1988-89). From 1984 to 1986 he was an Associate in the Harvard Medical School, Boston, U.S.A. and an employee of ImmunoGen Inc., where he worked on the first generation of anti-cancer antibody conjugates.
Dr. Moroney studied chemistry in his native New Zealand, where he completed an M.Sc with 1st class honours in 1981 and was a Commonwealth Scholar to the University of Oxford, where he completed a D. Phil in Chemistry in 1984. In 2002, Dr. Moroney was awarded the German Cross of the Order of Merit by Dr. Johannes Rau, President of the Federal Republic of Germany, for his services to the biotechnology industry.
|
Mr Philip Nelson,
Senior Manager Recovery Technology Support,
Abgenix
Philip Nelson has spent the last 18 years working on the production and process development of large scale, recombinant pharmaceuticals. In that time Mr. Nelson has worked at Genentech, Connetics, Millipore and Abgenix. He is currently responsible for the transfer of MAb purification processes from Process Science to Manufacturing and the investigation of purification deviations at Abgenix, Inc. Mr. Nelson received his B.S degree in Genetics from U.C. Berkeley.
|
 Prof Mats Ohlin,
Department of Immunotechnology,
Lund University
Professor of Immunotechnology at Lund University (Lund, Sweden) since 2003. His research has a focus on human monoclonal antibodies, combinatorial library approaches, and human antibody repertoires.
|
 Dr Jane Osbourn,
Vice President Biologics Discover,
Cambridge Antibody Technology
Jane Osbourn obtained a BA in Natural Sciences (Biochemistry) from the University of Cambridge. Following this she went on to complete a Ph.D. at the John Innes Centre for Plant Science Research in Norwich, focussing on plant responses to viral infections. Jane then moved into medical research, taking a British Heart Foundation Post Doctoral Fellowship to study the regulation of gene expression in smooth muscle cells at the Dept. of Medicine at Addenbrooke's Hospital in Cambridge. In 1993 she moved to CAT where she has held a number of positions involved in product and technology development. Her current position is Vice President of Oncology within the Drug Discovery department.
|
 Prof. Andy Porter,
Chief Scientific Officer,
Haptogen Ltd
Andy retains his academic position at the University of Aberdeen where he holds the chair for Biotechnology and is also Deputy Director of the Institute for Medical Sciences. He has more than 100 peer reviewed publications and is recognised as a leading expert on the isolation of genetically modified antibodies specific for small molecules. Andy is a co-founder of both Haptogen and another Aberdeen University spin-out, Remedios. He was recently awarded a prestigious commercialisation fellowship in Biotechnology by the Royal Society of Edinburgh and Scottish Enterprise and a finalist at the Ernest & Young Entrepreneur of the Year Awards.
|
Dr Alex Price,
Sales & Marketing Support Executive,
PharmaVentures
|
Dr Gabriele Schaeffner,
Principal Consultant, Drug Development Consulting Practice,
PAREXEL International GmbH
|
 Dr Wolfgang Teschner,
Senior Manager Plasma Product Development,
Baxter AG
Diploma in Biology, University of Regensburg, Regensburg, Germany
Diploma thesis: "Investigations on folding of octopindehydrogenases" Department of Biophysics and Physical Biochemistry (Prof. Dr. Rainer Jaenicke).
Ph.D. University of Regensburg, Regensburg, Germany
Thesis: "Folding of octopindehydrogenase from Pecten jacobaeus" Department of Biophysics and Physical Biochemistry (Prof. Dr. Rainer Jaenicke).
1984-1987 Research Associate (3 years)
Department of Biophysics and Physical Biochemistry;
University of Regensburg.
1987-1989 Fellowship from the European Molecular Biology Organization at the Centre National de la Recherche Scientifique, Gif-sur-Yvette, France.
Research on stability and folding of phosphofructokinase from E. coli (department of Prof. Dr. Jean-Renaud Garel, professor of the Institute Pasteur, Paris).
1990-1996 Member of process monitoring and process development team (Head, Dr. Y. Linnau), Immuno AG, Vienna, Austria (after 1997, Hyland-Immuno Division, Baxter Healthcare AG).
1996 – 1999 Manager and head of process monitoring and process development “Immunoglobulines and Albumin” department, Baxter AG, Vienna Austria.
1999 – 2004 Manager and head of plasma product development “Immunoglobulines and Albumin” department, Baxter AG, Vienna Austria.
01.2005 Promotion to senior manager as head of plasma product development / product support department
|
 Dr Lincoln Tsang,
Partner,
Arnold & Porter LLP
Dr. Lincoln Tsang practises European and UK domestic law at the London office of Arnold & Porter LLP, an international law firm. His practice covers both contentious and non-contentious matters relating to pharmaceuticals, food, cosmetics and devices. He serves as a non-executive director on the management board of National Institute of Biological Standards and Control; and a member of the British Pharmacopoeia Commission’s Committee on Biological Materials; a member of Cancer Research UK Policy Advisory Committee. He is currently Chairman of the BioIndustry Association’s Regulatory Affairs Advisory Committee. He also advises foreign governments, trade associations and not-for-profit and/or charity organisations on various technical and legal matters pertaining to medicines and devices regulation. He is a former Head of Biologicals and Biotechnology of the United Kingdom Regulatory Authority responsible for a wide range of UK and European policy work. He held memberships and chairmanships of various advisory groups at the European Medicines Agency and at an international level, and has authored a number of regulatory guidelines. He was an advisor to the World Health Organisation (WHO) concerning technical and legal aspects of international trade of biological products. He writes and speaks widely on legal and technical matters relating to pharmaceuticals and life sciences industries.
|
 Prof Jan van de Winkel,
Chief Scientific Officer,
Genmab A/S
Dr. Jan G.J. van de Winkel is Executive Vice President and Chief Scientific Officer of Genmab A/S, and holds a Professorship at Utrecht University (The Netherlands). His research focuses on the biological role and clinical application of antibodies. Within his laboratory clinical implications of Fc receptor heterogeneity, and novel therapeutic strategies for cancer, autoimmune disorders and infectious diseases are studied. Dr. van de Winkel is widely recognized, as one of the leading scientists in the study of antibodies and their interaction with the immune system. His research is supported by grants from Utrecht University, The Dutch Cancer Foundation, The Netherlands Organization for Scientific Research and the National Rheumatism Foundation. Dr. van de Winkel has been responsible for a number of patents and patent applications and is the author of over 240 scientific publications.
Dr. van de Winkel received his M.Sc. degree in Biology (1985) and a Ph.D. in Immunology (1988) from the University of Nijmegen (The Netherlands). He conducted postdoctoral work at the University Hospital Utrecht and Ohio State University, before returning to Utrecht University in 1991. He is currently a part-time Professor of Immunotherapy at the University Medical Center in Utrecht. In 1997 he set up a research unit for Medarex and served as Vice President and Scientific Director of Medarex Europe until 2000. Dr. van de Winkel co-founded Genmab in February 1999 and served as CSO since Genmab’s inception.
|
 Dr Trudi Veldman,
Director Biologics Generation,
Abbott Bioresearch Centre
|
 Mr Jan Visser,
Director, Small Scale Cell Culture & Development,
Diosynth Biotechnology
Jan Visser is Director Small Scale Cell Culture and Development at Diosynth Biotechnology (Oss, The Netherlands). His group is responsible for the development and scale-up of cell culture processes, investigation and implementation of new technologies and manufacturing of small scale (up to 100L) clinical and commercial batches. Diosynth Biotechnology is part of Organon and provides process development and cGMP manufacturing services for (bio)pharmaceutical products.
Jan Visser received his PhD in 1997 in microbiology from the Delft University of Technology. He has worked in the Biological Food Processing Department and Oral Care Department at Unilever Research as a research scientist and project manager, after which he joined Diosynth Biotechnology in 2002.
|
 Dr Philip M Webber,
European Patent Attorney,
Frank B Dehn & Co (UK)
Philip obtained his first degree from Cambridge University, UK, (Natural Sciences, Genetics) and then carried out research on the regulation of brain-specific genes at Warwick University, UK, where he obtained his PhD. He qualified as a UK Chartered Patent Agent and European Patent Attorney with Frank B. Dehn & Co. and is now a partner in their chemical/bioscience group. He has a worldwide client-base including clients from the UK, Scandinavia, the US and Japan. Amongst other things, his work involves the preparation and filing of patent applications in Europe and throughout the world; acting for his clients in opposition procedures at the European Patent Office; and searching for and advising his clients on the relevance of competitors' patents. He is an active member of the Biotechnology Committee of the UK Chartered Institute of Patent Agents. He has spoken at a number of European and UK conferences and on BBC Radio on the patenting of biotech inventions, as well as publishing a number of papers in this area. Philip was highly praised in last year’s Legal 500 - widely considered as the definitive guide to legal firms in over 70 countries. The Legal 500 also rated Frank B. Dehn & Co. as a top-tier patent firm.
|
 Dr Paul Weiss,
President,
Gala Biotech
Dr. Paul Weiss has been President of Middleton, WI-based Gala Biotech business unit of Cardinal Health since February 2002. Dr. Weiss served as a Director on Gala’s Board from 1998 to 2001, when he joined the management team as Senior Vice President of Business Development. While serving on Gala’s Board, he also held the position of Vice President of Technology and Product Licensing at 3-Dimensional Pharmaceuticals, a Philadelphia, PA-based small molecule drug discovery biotech company that went public in 2001 and was acquired by J&J in 2003. Prior to joining 3-Dimensional Pharmaceuticals, Dr. Weiss was Director of Licensing for Wyeth-Ayerst Laboratories, a division of Wyeth Pharmaceuticals, also located in the Philadelphia, PA.
In October 2003, Gala was acquired by Cardinal Health, a Fortune 16 company with over 55,000 employees worldwide and $75 billion in sales. Gala Biotech now operates as a business unit of Cardinal Health. Currently, Dr. Weiss also serves on the Board of Directors of Alfacell Corporation, a Bloomfield, NJ-based biotech company focused on the discovery and commercialization of novel cancer treatments. He is also on the Board of the Wisconsin Biotech and Medical Device Association. Dr. Weiss holds a PhD in Biochemistry and an MBA from the University of Wisconsin-Madison and a BSc in Biochemistry from Carleton University’s Institute of Biochemistry in Ottawa, Ontario, Canada.
|
 Dr Andreas Werner,
Head of Biopharmaceutical Production Management,
Boehringer Ingelheim
Dr. Andreas Werner began to study Biology at the University of Bielefeld, Germany in 1991 where he specialised in Genetics, Immunology and Biotechnology. In 1997 he obtained his MSc for his work on producing monoclonal antibodies in Hollow Fiber systems and stirred tank bioreactors and the evaluation of methods to preserve mammalian CHO cell cultures.
Subsequently until 1998 he worked on a BMBF project for the generation of an extracorporal bioartificial liver. In this project methods for mass cell cultivation of immortalised murine and human hepatocytes on microcarriers were established.
From 1998 to 2001 Dr. Werner investigated the molecular and cellular interaction of E-selectin and Granulocyte surface sugarmolecules and obtained his PhD at the Technical Faculty of the University of Bielefeld, Germany, for his studies on these inflammatory interactions.
After his appointment to become an Assistant Lecturer, he taught from 2001 to 2002 at the Institute of Cell Culture Technology in Bielefeld and focussed his work on medical biotechnology while establishing techniques for mass cell cultivation and differentiation of embryonic stem cells.
Since 2003 Dr. Werner has been working for the Corporate Division Biopharmaceuticals at the Boehringer Ingelheim GmbH in Germany as a Corporate Manager and is responsible for the strategic production management of biopharmaceuticals.
|
 Dr John Wijdenes,
General Director,
Diaclone SAS
|
Dipl.-Ing Frank Wolpers,
Industrial Sales Director Europe,
Perbio Science Deutschland GmbH
|
 Dr Clive Wood,
CSO,
Dyax
Clive R. Wood, Ph.D. has served as the Senior Vice President, Discovery Research and Chief Scientific Officer at Dyax Corp. since August 2003.
Prior to this, Dr. Wood spent 17 years at Genetics Institute (GI) and its successor, Wyeth Research, where he held a number of drug discovery research positions. Most recently, Dr. Wood held the position of Senior Director and Acting Head of Inflammation Discovery Research at Wyeth Research in Cambridge, MA. At GI and Wyeth, Dr. Wood focused on respiratory diseases, transplantation, immunology, hematopoiesis and antibody technologies. Prior to joining GI in 1986, Dr. Wood worked for four years at Celltech Ltd. He received his Biochemistry BSc and PhD degrees from Imperial College, University of London, UK.
|
David Young,
Chief Scientific Officer,
ARIUS
|
|
|
|
